Meeting
2024 ASCO Genitourinary Cancers Symposium
Real-world metastatic renal cell carcinoma (mRCC) treatment trends in Mexico: A public vs private sector analysis.
Authors
Iván Romarico González Espinoza
Hospital Ángeles Puebla, Puebla, Mexico
Iván Romarico González Espinoza , Lizbett Vanessa Garcia Montes , Osvaldo Hernandez Flores , Yuly Andrea Remolina Bonilla , Luis Arturo Sanchez-Trujillo , Maria del Socorro Isabel Rios Mercado , Diana Jaimes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 397)
DOI
10.1200/JCO.2024.42.4_suppl.397
Abstract #
397
Poster Bd #
F21
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
First Author: Neil J. Shah
Poster
2023 ASCO Genitourinary Cancers Symposium
Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI.
First Author: Jeffrey Thomas Yorio
Poster
2020 Genitourinary Cancers Symposium
Optimal sequence strategy with nivolumab and targeted therapy in patients with metastatic renal cell carcinoma (mRCC).
First Author: Juliette Logeart
Poster
2013 Genitourinary Cancers Symposium
Real-world treatment patterns in third-line patients with metastatic renal cell carcinoma (mRCC): The changing landscape in the United States.
First Author: Sumanta Kumar Pal